Novel prodrugs for targeting diagnostic and therapeutic radionuclides to solid tumors

Area of Science:

• Oncology
• Radiopharmaceutical Chemistry
• Drug Delivery Systems

Background:

• Conventional cancer therapeutics exhibit limited efficacy due to issues like poor drug distribution, toxicity in normal tissues, and multidrug resistance.
• Existing treatments often fail to achieve sufficient drug concentration or retention within solid tumors.
• Challenges include drug diffusion, non-uniform distribution, normal tissue toxicity, cell permeability requirements, low tumor uptake, and lack of drug retention.

Purpose of the Study:

• To develop an innovative technology for actively concentrating and permanently entrapping radiopharmaceuticals specifically within solid tumors.
• To address the limitations of current cancer therapeutics, including poor drug distribution and retention.
• To enable noninvasive sensing and effective therapy of solid tumors for personalized medicine.

Main Methods:

• Development of a novel technology for active concentration and permanent entrapment of prodrugs.
• Utilizing radioimaging and radiotherapeutic prodrugs for targeted delivery.
• Focusing on overcoming challenges in drug diffusion, retention, and tumor uptake.

Main Results:

• The technology aims to actively concentrate and permanently entrap prodrugs within solid tumors.
• This approach is designed to overcome common failure points in cancer therapy.
• Potential for enhanced tumor detection, diagnosis, and treatment through coupled noninvasive sensing and therapy.

Conclusions:

• The innovative technology offers a promising strategy to surmount existing challenges in cancer therapy.
• Active concentration and permanent entrapment of radiopharmaceuticals in tumors can improve treatment outcomes.
• This approach facilitates personalized medicine by closely coupling tumor detection, diagnosis, and treatment.